Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.481EUR
−145.80 MEUR
57.56 MEUR
99.88 M
About Fate Therapeutics, Inc.
Sector
Industry
CEO
J. Scott Wolchko
Website
Headquarters
San Diego
Employees (FY)
181
Founded
2007
FIGI
BBG005CNC5T8
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
FATE. Have Faith in this stock.FATE. Have Faith in this stock.
Could snap back to previous channel fast.
Big institional value and insider value.
Gap Down/Bad News Event
No earnings report as of late so I tried to find out what the deal is. Looks like an analyst' downgrade on Friday and some other bad news.
Short is over 24%.
Makes you scratch your head and think WOW!
No recommendation/Dust needs to settle and I guess even dirt can get cheaper )o:
FATE | Incoming Rally - Oversold | LONGFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma,
FATEFATE is an interesting company, just developing. There are about 480 thousand in cash, an annual loss of 173 thousand, Has 8 studies in 1 phase. Probably, it will “accumulate” one more year before significant phase studies (3), which corresponds to the negative scenario. And 2 in partnership with Ja
Bullish Expecting a sympathy bounce Please review any tips or thoughts is helpful.
1 to 4 risk to reward
Stop loss 69
Short term price target $78
Risking $2 for $8 a share.
FATE Yanagi Lives! Will swing this dead cat bounce3 to 4 weeks on the 30 min chart. Staying patient, hoping bullish wedge forms before the dead cat bounce swing. Some Bollinger band squeezes energy behind it. Let's see!
NASDAQ:FATE
FATE Bullish Triangle Pattern Looking to place some Leaps on FATE as hedge funds pile up on this biotech stock
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange FATE THERAPEUTICS DL-,001 stocks are traded under the ticker F6T.
FATE THERAPEUTICS DL-,001 is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
F6T earnings for the last quarter are −0.41 EUR per share, whereas the estimation was −0.47 EUR resulting in a 13.83% surprise. The estimated earnings for the next quarter are −0.44 EUR per share. See more details about FATE THERAPEUTICS DL-,001 earnings.
FATE THERAPEUTICS DL-,001 revenue for the last quarter amounts to 1.52 M EUR despite the estimated figure of 1.39 M EUR. In the next quarter revenue is expected to reach 1.54 M EUR.
Yes, you can track FATE THERAPEUTICS DL-,001 financials in yearly and quarterly reports right on TradingView.
F6T net income for the last quarter is −39.97 M EUR, while the quarter before that showed −42.73 M EUR of net income which accounts for 6.45% change. Track more FATE THERAPEUTICS DL-,001 financial stats to get the full picture.
No, F6T doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, F6T shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FATE THERAPEUTICS DL-,001 stock right from TradingView charts — choose your broker and connect to your account.
As of May 8, 2024, the company has 181.00 employees. See our rating of the largest employees — is FATE THERAPEUTICS DL-,001 on this list?
We've gathered analysts' opinions on FATE THERAPEUTICS DL-,001 future price: according to them, F6T price has a max estimate of 11.08 EUR and a min estimate of 4.62 EUR. Watch F6T chart and read a more detailed FATE THERAPEUTICS DL-,001 stock forecast: see what analysts think of FATE THERAPEUTICS DL-,001 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. FATE THERAPEUTICS DL-,001 EBITDA is −156.04 M EUR, and current EBITDA margin is −250.78%. See more stats in FATE THERAPEUTICS DL-,001 financial statements.